Perceptive eClinical
Perceptive eClinical is recorded as a service provider in 123 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 123 trials · Latest update first
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
A Multicentre, Open-label, Randomised, Phase IV Study to Investigate Acalabrutinib Monotherapy Compared to Investigator’s Choice of Treatment in Adults (> 18 Years) With Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairment
Sponsor AstraZeneca AB
- Start (EU)
- Latest update
- Estimated end
An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease
Sponsor BeOne Medicines I GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination with Pomalidomide and Dexamethasone Versus Standard of Care in Patients with Multiple Myeloma who Have Received One to Three Prior Lines of Therapy
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
C4221016 - A Phase 3, Randomized, Double-Blind Study of Encorafenib and Binimetinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants with BRAF V600E/K Mutation-Positive Metastatic or Unresectable Locally Advanced Melanoma
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
Phase I/II, open label, multicenter study of rapcabtagene autoleucel in adult patients with CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Study of Pembrolizumab (MK-3475) every 6 weeks (Q6W) in Participants with Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM])
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Two-Part Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of MK-7480 in Healthy Participants
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available1 trial-level finding · Read insights
- Amendment 03 added Panel D to evaluate safety, tolerability, and pharmacokinetics at higher MK-7480 doses in light of emerging pharmacokinetic data.
These findings describe the trial, not the service provider’s performance or responsibility.
A Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of MK-3508 in Healthy Participants
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available4 trial-level findings · Read insights
- Amendments added two panels to explore higher MK-3508 doses.
- Planned doses were revised downward based on emerging pharmacokinetic data.
- An amendment added inclusion-criteria requirements and an additional stopping criterion.
- An amendment clarified concomitant-medication restrictions and study procedures and added safety monitoring.
These findings describe the trial, not the service provider’s performance or responsibility.
A Multiple-Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-4318 in Healthy Participants
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available1 trial-level finding · Read insights
- Adult participants were recruited at one study site in Belgium, with 32 participants enrolled.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants with First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61)
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
Long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (FOCUS)
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
ROSY-F: Roll-Over Study for Participants Who Have Completed a Previous Study with Benralizumab (Fasenra) and Are Judged by the Investigator to Clinically Benefit from Continued Treatment
Sponsor AstraZeneca AB
- Start (EU)
- Latest update
- Estimated end
A 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Fluticasone Propionate/Albuterol Sulfate Combination compared to Fluticasone Propionate, Albuterol Sulfate or Placebo delivered by Multidose Dry Powder Inhaler in Participants 12 Years and Older with Asthma
Sponsor Teva Branded Pharmaceutical Products R&D LLC
- Start (EU)
- Latest update
- Estimated end
A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients with Multiple System Atrophy (TOPAS-MSA)
Sponsor Teva Branded Pharmaceutical Products R&D LLC
- Start (EU)
- Latest update
- Estimated end
A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab versus Risankizumab in the Treatment of Participants with Moderately to Severely Active Crohn’s Disease
Sponsor Janssen Cilag International
- Start (EU)
- Latest update
- Estimated end
An Open Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB 11417) as Monotherapy and in Combination with Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Perceptive eClinical?
The 2026-10-09 snapshot links Perceptive eClinical to 123 distinct CTIS trials. Recorded services include Interactive response technology (IRT), EUB Call center and medical escalation service, Emergency Unblinding Call Center, Imaging, among 27 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Perceptive eClinical?
The most frequently recorded therapeutic areas are Haematological Malignancies, Solid Tumor Oncology, Respiratory, Dermatology. Recorded phases include Phase 3, Phase 2, Phase 1, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Perceptive eClinical conducted?
The linked trials record locations in 25 countries, including Spain, Italy, France, Germany, Poland. These are trial locations, not confirmed office locations or countries where Perceptive eClinical delivered services.
What can this page tell me about Perceptive eClinical's trial experience?
Browse 123 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 5 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Perceptive eClinical. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Perceptive Eclinical Limited